Longeveron Inc. (NASDAQ:LGVN) Director Purchases $45,120.00 in Stock

Longeveron Inc. (NASDAQ:LGVN) Director Rock Soffer acquired 12,000 shares of the company’s stock in a transaction on Wednesday, October 13th. The stock was purchased at an average cost of $3.76 per share, for a total transaction of $45,120.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Rock Soffer also recently made the following trade(s):

  • On Monday, October 11th, Rock Soffer acquired 3,900 shares of Longeveron stock. The stock was purchased at an average cost of $3.45 per share, for a total transaction of $13,455.00.

LGVN traded up $0.22 during trading on Wednesday, hitting $3.81. The stock had a trading volume of 181,790 shares, compared to its average volume of 423,842. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.12 and a current ratio of 10.12. The company’s 50-day moving average price is $3.89 and its 200 day moving average price is $5.62. Longeveron Inc. has a twelve month low of $3.20 and a twelve month high of $12.48.

Longeveron (NASDAQ:LGVN) last announced its quarterly earnings data on Friday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter. The business had revenue of $0.49 million for the quarter.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Longeveron by 811.5% during the 2nd quarter. Vanguard Group Inc. now owns 131,260 shares of the company’s stock worth $1,067,000 after purchasing an additional 116,860 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Longeveron during the 2nd quarter worth $311,000. Matrix Asset Advisors Inc. NY boosted its position in shares of Longeveron by 16.7% during the 2nd quarter. Matrix Asset Advisors Inc. NY now owns 35,000 shares of the company’s stock worth $285,000 after purchasing an additional 5,000 shares in the last quarter. Geode Capital Management LLC purchased a new stake in shares of Longeveron during the 2nd quarter worth $120,000. Finally, Private Capital Group LLC boosted its position in shares of Longeveron by 140.0% during the 3rd quarter. Private Capital Group LLC now owns 12,000 shares of the company’s stock worth $42,000 after purchasing an additional 7,000 shares in the last quarter. Institutional investors own 1.90% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.

Featured Article: How does inflation affect different investments?

Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.